Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
{{output}}
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with subs... ...
